Neurosense Therapeutics Ltd
NRSNW0.735USD
+0.185+33.64%
取引時間 （ET）15分遅れの株価
0.00時価総額
--直近12ヶ月PER
詳細情報 Neurosense Therapeutics Ltd 企業名
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
企業情報
企業コードNRSNW
会社名Neurosense Therapeutics Ltd
上場日Dec 09, 2021
最高経営責任者「CEO」Mr. Alon Ben-Noon
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地11 Hamenofim St.
都市HERZLIYA
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号4672562
電話番号97299531142
ウェブサイトhttps://www.neurosense-tx.com/
企業コードNRSNW
上場日Dec 09, 2021
最高経営責任者「CEO」Mr. Alon Ben-Noon
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sun, Feb 23
更新時刻: Sun, Feb 23
株主統計
種類
株主統計
株主統計
比率
Other
100.00%
株主統計
株主統計
比率
Other
100.00%
種類
株主統計
比率
Other
100.00%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
6
78.60K
0.00%
-114.75K
2025Q1
6
78.60K
0.00%
-114.75K
2024Q4
6
106.40K
0.00%
-91.99K
2024Q3
6
111.43K
0.00%
-96.87K
2024Q2
7
281.35K
0.00%
-114.32K
2024Q1
7
395.47K
0.00%
+21.94K
2023Q4
7
369.53K
0.00%
-28.20K
2023Q3
7
397.72K
0.00%
-24.43K
2023Q2
7
422.15K
0.00%
-55.70K
2023Q1
6
477.05K
0.00%
+29.79K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Clear Street LLC
65.76K
0%
+100.00
+0.15%
Mar 31, 2025
Citadel Advisors LLC
--
0%
-22.71K
-100.00%
Mar 31, 2025
Warberg Asset Management LLC
10.00K
0%
-7.94K
-44.25%
Mar 31, 2025
UBS Financial Services, Inc.
2.84K
0%
+2.75K
+2922.34%
Mar 31, 2025
Hudson Bay Capital Management LP
--
0%
-86.75K
-100.00%
Jun 30, 2024
BofA Global Research (US)
--
0%
-200.00
-100.00%
Dec 31, 2023
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
